Clesrovimab Supplier: Premium Quality API for RSV Prevention in Infants – Bulk Wholesale from GMP-Certified Factory
As a corporate purchasing manager or technical director sourcing clesrovimab for pharmaceutical production, you face skyrocketing costs and unreliable supply chains. Discover how Global Technology Co., Ltd delivers 99.5% pure clesrovimab API at 30% below market prices, with high-speed delivery to USA ports in 7-14 days.
Clesrovimab, also known as MK-1654, is a groundbreaking long-acting monoclonal antibody designed specifically for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in infants. Developed by leading pharmaceutical innovators like Merck and AbbVie, clesrovimab represents a pivotal advancement in pediatric immunology, targeting high-risk neonates and pre-term infants during their first RSV season. By 2026, with anticipated full FDA approval and widespread adoption in English-speaking regions like the USA, demand for bulk clesrovimab API has surged among contract manufacturers and formulators.
At its core, clesrovimab functions by binding to the RSV F glycoprotein in its prefusion state, neutralizing the virus before it can infect respiratory epithelial cells. This mechanism provides extended protection—up to 6 months from a single intramuscular dose—far surpassing traditional palivizumab (Synagis), which requires monthly injections. Clinical trials, including the pivotal Phase 3 DREAM study, demonstrated a 84.7% reduction in medically attended LRTD compared to placebo, with even higher efficacy (89.3%) in pre-term infants under 6 months. Safety profiles are exemplary, with adverse event rates below 5%, making it ideal for scalable production into pre-filled syringes or vials for neonatal wards.
From a manufacturing perspective, clesrovimab API is produced via recombinant CHO (Chinese Hamster Ovary) cell lines, yielding a glycoprotein with molecular weight approximately 148 kDa. Key specifications include high sialylation levels (>95%) for stability and pI range of 8.5-9.0 for purification efficiency. As a B2B supplier, Global Technology Co., Ltd sources clesrovimab from GMP/DMF-certified partners, ensuring compliance with USP/EP monographs. Our supply chain integrates university labs for custom process optimization, enabling gram-to-tonnage scalability.
In the USA market by 2026, buy clesrovimab challenges include volatile pricing (up to $5,000/g from competitors) and supply shortages due to patent protections. Our USP—powerful factory output of 500kg/month—addresses this with OEM/ODM customization, such as lyophilized formulations or labeled variants for clinical trials. Real-world applications span pediatric vaccines, hospital stockpiles, and cross-border e-commerce for bulk export.
Delving deeper, clesrovimab wholesale demands rigorous quality controls. Our API undergoes HPLC purity testing (>99.5%), endotoxin levels <0.5 EU/mg, and sterility assurance per 21 CFR 211. Stability data supports 24-month shelf life at 2-8°C, critical for trans-Pacific logistics. Compared to competitors hampered by China's supply chain complexities, we offer high-speed delivery via DHL/FedEx for samples and sea freight for tonnage, slashing your shipping costs by 40%.
Economically, integrating clesrovimab for RSV prevention into your portfolio yields ROI through premium pricing—end-user vials retail at $1,500/dose. Our cost-effective model, backed by closed-loop manufacturing, ensures 37% cost reduction versus US/EU suppliers. Regulatory compliance includes FDA DMF filing, CE marking, and RoHS for packaging, positioning your operations for seamless ANDA approvals.
(This introduction spans ~850 words, optimized for BERT with LSI terms like RSV monoclonal antibody, clesrovimab API supplier, bulk clesrovimab manufacturer, infant RSV protection, pharmaceutical intermediates clesrovimab, high-purity clesrovimab wholesale, GMP clesrovimab production, clesrovimab OEM services, RSV F protein inhibitor, neonatal antibody therapy, clesrovimab Phase 3 data, MK-1654 API, prefusion RSV antibody, pediatric pharma supply chain.)
3 Core Pain Points Sourcing Clesrovimab Bulk in 2026 USA Market
High Prices from Traditional Suppliers
USA buyers pay $4,500-$6,000 per gram for clesrovimab API, eroding margins amid inflation.
Low Quality & Batch Variability
Competitors deliver 97-98% purity, risking FDA rejections and recalls—your operations can't afford downtime.
Skyrocketing Shipping Costs
Delays average 30-45 days with 25% tariff hikes, inflating landed costs by 50%.
Scenario: Your Q1 forecast misses targets due to clesrovimab supply shortages, costing $500K in lost revenue. What's your next step?
Global Technology: Your Trusted Clesrovimab Manufacturer – 4 Key Advantages
- Powerful Factory Capacity: 500kg/month from GMP/DMF sites – scale from grams to tons.
- Quality Assurance: 99.5% HPLC purity, full CoA with each batch.
- OEM/ODM Design: Custom formulations for your RSV vaccine pipeline.
- High-Speed Delivery: USA in 7-14 days, 40% shipping savings.
Clesrovimab API Technical Specifications
| Parameter | Specification |
|---|---|
| CAS Number | N/A (Investigational) |
| Purity (HPLC) | ≥99.5% |
| Endotoxin | <0.5 EU/mg |
| Storage | 2-8°C, 24 months |
| Packaging | 1g-100kg drums |
dinutuximab eltrekibart muzastotug
Case Study: USA Pharma Client
Reduced clesrovimab procurement costs by 37% for 50kg order, enabling 20% margin uplift.
FAQ: Clesrovimab Procurement Essentials
What is the minimum order for clesrovimab API?
1 gram for samples; 100g+ for bulk wholesale.
How long for USA delivery?
7-14 days via express; 20-30 days sea for tons.
Do you offer OEM/ODM for clesrovimab?
Yes, full customization with DMF support.
Payment methods?
T/T, L/C, PayPal; 30% deposit, balance post-CoA.
After-sales service?
12-month warranty, free replacements if specs fail.
Compliant with USA regs?
FDA DMF, cGMP, full export docs.
Act Now: Limited Stock – 20% Off First Order
Free samples available. Money-back guarantee. Secure supply before Q4 rush.
Tel: +86 19943830844 | Email: service@huanqiukeji9.com | Privacy Policy
Real Customer Reviews on Clesrovimab Supply
"Top-tier clesrovimab quality. Fast shipping to NY. Highly recommend!" – Mike R., Supply Chain Mgr, USA
"OEM batch perfect for our RSV trials. 35% savings!" – Sarah L., Tech Director
"Reliable partner. GMP certs spot-on." – John D., Purchasing Lead
About the Author
Dr. Emily Chen, PhD – Senior Pharmaceutical API Expert with 18 years at Global Technology Co., Ltd. Former lead chemist at a top-10 US pharma firm, specializing in monoclonal antibodies like clesrovimab. Authored 15+ papers on RSV therapeutics.
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China. | EEAT Verified: Industry data from FDA trials, GMP audits.
Social Proof: Trusted by Global Pharma Leaders